The United Kingdom has approved the use of medical cannabis for chronic pain conditions that have not responded to other treatments. The decision, made by the Medicines and Healthcare products Regulatory Agency (MHRA), will allow doctors to prescribe cannabis products for patients with severe chronic pain. The United Kingdom has approved the use of medical cannabis for chronic pain conditions that have not responded to other treatments. The decision, made by the Medicines and Healthcare products Regulatory Agency (MHRA), will allow doctors to prescribe cannabis products for patients with severe chronic pain.

This is a significant development for patients in the UK who are living with chronic pain. Medical cannabis has been shown to be effective in treating a variety of pain conditions, including neuropathic pain, cancer pain, and chronic pain associated with inflammatory conditions.

The MHRA’s decision is based on a growing body of evidence that supports the safety and efficacy of medical cannabis. The agency has also taken into account the recommendations of the National Institute for Health and Care Excellence (NICE), which has published guidelines on the use of medical cannabis for chronic pain.

The use of medical cannabis is still tightly controlled in the UK. Cannabis products can only be prescribed by specialist doctors, and patients must meet certain criteria to be eligible for treatment. However, the MHRA’s decision is a positive step towards making medical cannabis more accessible to patients who need it.

The United Kingdom has approved the use of medical cannabis for chronic pain conditions that have not responded to other treatments. The decision, made by the Medicines and Healthcare products Regulatory Agency (MHRA), will allow doctors to prescribe cannabis products for patients with severe chronic pain.

This is a significant development for patients in the UK who are living with chronic pain. Medical cannabis has been shown to be effective in treating a variety of pain conditions, including neuropathic pain, cancer pain, and chronic pain associated with inflammatory conditions.

The MHRA’s decision is based on a growing body of evidence that supports the safety and efficacy of medical cannabis. The agency has also taken into account the recommendations of the National Institute for Health and Care Excellence (NICE), which has published guidelines on the use of medical cannabis for chronic pain.

The use of medical cannabis is still tightly controlled in the UK. Cannabis products can only be prescribed by specialist doctors, and patients must meet certain criteria to be eligible for treatment. However, the MHRA’s decision is a positive step towards making medical cannabis more accessible to patients who need it.

The United Kingdom approved the use of medical cannabis for chronic pain conditions that have not responded to other treatments on 10th August, 2023¹. This decision was made by the Medicines and Healthcare products Regulatory Agency (MHRA) and allows doctors to prescribe cannabis products for patients with severe chronic pain¹.

Learn more:

1. england.nhs.uk2. bmj.com3. britishpainsociety.org4. healtheuropa.com5. pharmaceutical-journal.com6. doi.org